circRNA basic information
circBase ID: -
Name: hsa_circ_E-cadherin
Synonym: circ-E-cadherin
Host Gene: E-cadherin
Genomic location(hg19): -
Genomic location(hg38): -
Subcellular localization: not tested
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0007254
MONDO name: breast cancer
Disease details: breast cancer
Disease DO ID:
 1612
Disease MeSH ID:
 -
Disease NCIt ID:
 C9335
Disease ICD11 ID:
 1047754165
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

breast cancer tissues; paired normal tissues; normal breast tissue; peripheral blood mononuclear cells
Cell lines:

MDA-MB-231; MDA-MB-468; MDA-MB-453; AU565; SKBR-3; ZR7530; BT474; BT549; MCF-7; MCF-10A; 4T1; e0771
In vivo animal model:

cell line-derived xenograft; syngeneic model
circRNA-disease information
Expression pattern:
UP
Associated gene: C-E-cad, EGFR, CXCL8, STAT3, AKT, MDSCs, PMN-MDSCs
Associated microRNA: -
Biological function: Promotes MDSC recruitment and survival, especially PMN-MDSC accumulation; inhibits CD4+ and CD8+ T-cell infiltration and function through MDSC recruitment; promotes tumor growth; enhances glycolysis and suppressive phenotype transition in MDSCs; targeting C-E-cad increases anti-PD-1 antibody efficacy.
Molecular mechanism: circ-E-cadherin encodes the protein C-E-cad; C-E-cad directly activates EGFR signaling and downstream AKT/STAT3, promotes CXCL8 transcription to recruit MDSCs, and acts through paracrine signaling on MDSCs to promote suppressive phenotype transition and glycolytic metabolic reprogramming.
Biological pathway or process:

EGFR (promotes); PI3K/AKT (promotes); JAK/STAT (promotes); immune regulation (promotes); glycolysis (promotes); proliferation (promotes); drug resistance (promotes); other pathway/process (promotes)
Detected method:
Q
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RT-qPCR; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; Flow Cytometry（Non-apoptosis/cycle）; Transfection; Transwell Assay; Luciferase Reporter Assay; ELISA; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis
Clinical significance:

circ-E-cadherin/C-E-cad is upregulated in breast cancer patients and predicts a poor prognosis; C-E-cad is a potential therapeutic target whose blockade enhances anti-PD-1 therapy.
Description:

circ-E-cadherin is upregulated in human breast cancer and encodes the protein C-E-cad, whose high expression is associated with shorter overall survival. C-E-cad activates EGFR/AKT/STAT3 signaling to induce CXCL8 transcription, promoting PMN-MDSC recruitment and immunosuppression, while also acting on MDSCs to enhance glycolytic reprogramming. Targeting C-E-cad suppresses MDSC-mediated immune evasion and improves anti-PD-1 therapeutic efficacy.
Confidence score:

0.7887
Other information
Title:

Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells.

Journal: Pharmacological research
Published: 2024
PubMed ID: 38704109
Study type:

combined biological and clinical study
Data availability: Supplementary data associated with this article can be found in the online version at doi:10.1016/j.phrs.2024.107204; No data was used for the research described in the article.
Code availability: -